Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands |
Ayala Purchase Agreement
Common stock
|
Ayala Purchase Agreement
Additional Paid-in Capital
|
Ayala Purchase Agreement |
License agreement with Zentalis Pharmaceuticals, Inc
Common stock
|
License agreement with Zentalis Pharmaceuticals, Inc
Additional Paid-in Capital
|
License agreement with Zentalis Pharmaceuticals, Inc |
ATM
Common stock
|
ATM
Additional Paid-in Capital
|
ATM |
Public offering
Common stock
|
Public offering
Additional Paid-in Capital
|
Public offering |
Common stock |
Additional Paid-in Capital |
Accumulated Other Comprehensive Income |
Accumulated Deficit |
Total |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance at Dec. 31, 2022 | $ 1 | $ 132,653 | $ (116,001) | $ 16,653 | |||||||||||||
Balance (shares) at Dec. 31, 2022 | 12,128,843 | ||||||||||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||||||
Share-based compensation expense | 1,200 | 1,200 | |||||||||||||||
Issuance of common stock | $ 34 | $ 34 | 221 | 221 | |||||||||||||
Issuance of common stock ( in shares) | 5,925 | 55,250 | |||||||||||||||
Vesting of restricted stock awards | 24 | 24 | |||||||||||||||
Vesting of restricted stock awards (shares) | 4,166 | ||||||||||||||||
Net Income (Loss) | (4,270) | (4,270) | |||||||||||||||
Balance at Mar. 31, 2023 | $ 1 | 134,132 | (120,271) | 13,862 | |||||||||||||
Balance (shares) at Mar. 31, 2023 | 12,194,184 | ||||||||||||||||
Balance at Dec. 31, 2023 | $ 4 | 342,663 | $ 22 | (222,807) | 119,882 | ||||||||||||
Balance (shares) at Dec. 31, 2023 | 43,251,778 | ||||||||||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||||||
Share-based compensation expense | 2,159 | 2,159 | |||||||||||||||
Issuance of common stock | $ 50,645 | $ 50,645 | $ 23,388 | $ 23,388 | $ 2 | $ 215,408 | $ 215,410 | ||||||||||
Issuance of common stock ( in shares) | 2,175,489 | 2,298,586 | 11,500,000 | ||||||||||||||
Exercise of stock options | 171 | $ 171 | |||||||||||||||
Exercise of stock options (shares) | 125,704 | 137,112 | |||||||||||||||
Exercise of common stock warrants (in shares) | 342,686 | ||||||||||||||||
Unrealized loss on marketable securities | (18) | $ (18) | |||||||||||||||
Net Income (Loss) | (129,492) | (129,492) | |||||||||||||||
Balance at Mar. 31, 2024 | $ 6 | 637,861 | $ 4 | $ (352,299) | 285,572 | ||||||||||||
Balance (shares) at Mar. 31, 2024 | 59,694,243 | ||||||||||||||||
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||||||||||||||
Exercise of common stock warrants | $ 3,427 | $ 3,427 |
X | ||||||||||
- Definition Number of common stock warrants exercised during the period. No definition available.
|
X | ||||||||||
- Definition Value of common stock warrants exercised. No definition available.
|
X | ||||||||||
- Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. No definition available.
|
X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Number of shares issued which are neither cancelled nor held in the treasury. No definition available.
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Value of stock issued as a result of the exercise of stock options. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|